Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

@inproceedings{Fujita2014RenalSG,
  title={Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action},
  author={Yoshihito Fujita and Nobuya Inagaki},
  booktitle={Journal of diabetes investigation},
  year={2014}
}
Type 2 diabetes is characterized by impaired insulin secretion from pancreatic β-cells and/or reduced response of target tissues to insulin. Good glycemic control delays the development and slows the progression of micro- and macrovascular complications. Although there are numerous glucose-lowering agents in clinical use, only approximately half of type 2 diabetic patients achieve glycemic control, and undesirable side-effects often hamper treatment in those treated with the medications. There… CONTINUE READING
Highly Cited
This paper has 89 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

90 Citations

0102020152016201720182019
Citations per Year
Semantic Scholar estimates that this publication has 90 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 87 references

Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data

SD Prato
Diabetes • 2013

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

FJ Lavalle-Gonz alez, A Januszewicz, J Davidson
Diabetologia • 2013

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

K Stenl€ of, WT Cefalu, KA Kim
Diabetes Obes Metab • 2013